Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.
Syncona Ltd has underscored its gene therapy commitment by injecting £85m into Freeline Therapeutics via a series B financing that will allow the UK-based biotech to drive its leading programs in hemophilia B and Fabry disease through clinical development, its chairman told Scrip.
Freeline’s technology uses engineered adeno-associated virus (AAV) vectors for treating bleeding and other debilitating disorders. Its proprietary AAV vector technology...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
